Poster Tour 03: Liver health, fibrosis and advanced disease
Tracks
Track 1
| Friday, August 14, 2026 |
| 11:05 AM - 11:35 AM |
Speaker
VH2026
Welcome & Introduction
11:05 AM - 11:10 AMBiography
Mrs Emily Ward
Nurse Practitioner - Hepatology
Justice Health And Forensic Mental Health Network
Improving Timely Linkage to Care for Hepatitis B/D and Advanced Liver Disease patients: Outcomes of a Monthly Health Condition Audit Initiative
11:10 AM - 11:15 AMBiography
I have been a Registered Nurse for 12 years, predominantly working within the custodial setting across primary and population health. I have recently completed my Nurse Practitioner studies and am awaiting endorsement as a Nurse Practitioner in Hepatology.
Dr David Goodman
Senior Research Associate
Kirby Institute
To Screen or Not to Screen, before DAA Therapy? A Decision Curve Analysis of Age-Based Fibrosis Screening Strategies
11:15 AM - 11:20 AMBiography
Dr. David Goodman-Meza is a Senior Research Associate at the Kirby Institute in the University of New South Wales and a Staff Specialist at St Vincent's Hospital Sydney and Parklea Correctional Centre. He is a specialist in Infectious Diseases and Addiction Medicine.
Kirsty Rundle
Harm Reduction Nurse
DISC Trust - Rodger Wright Community Clinic
Getting on track and doing what we should: Addressing gaps in Hepatitis C treatment within Mental Health Services
11:20 PM - 11:25 PMBiography
Kirsty has over 30 years nursing experience primarily within mental health services with the last 10 years having specialised in physical health outcomes for consumers within Specialist Mental Health Services Te Whatu Ora Waitaha Canterbury.
Dr Heather Valerio
Research Fellow
The Kirby Institute, UNSW Sydney
Reductions in prevalence of advanced liver fibrosis among people who inject drugs in the direct-acting antiviral era: The ETHOS Engage Study
11:25 AM - 11:30 AMBiography
Heather is a postdoctoral research fellow in the Viral Hepatitis Clinical Research Program at the Kirby Institute. Her main area of focus is enhancing the equity of viral hepatitis elimination, particularly for people who inject drugs, women, children, and other populations who are underserved by the current standard of care.
Dr Anna Hawkes
CEO
Hepatitis Queensland
Liver cancer and viral hepatitis in Queensland – a new report.
11:30 AM - 11:35 AMBiography
Adjunct Associate Professor Anna Hawkes is CEO of Hepatitis Queensland. She has over 30 years’ executive experience leading policy, research and program delivery championing equitable health outcomes for marginalised communities.
